Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579096 · ClinicalTrials.gov registry record · Phase 4
CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 950
- Enrollment target
NCT02579096: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT02579096 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 950 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02579096, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 950 participants
- Enrollment target
Study Summary
This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attacks. These therapies have never been compared at appropriate doses. Further, they will be studied in patients with kidney disease for the first time.
Interventions
- DRUG allopurinol capsule, 100-800 mg by mouth once daily
- DRUG febuxostat tablet 40-120 mg by mouth once daily
- DRUG Placebo, vehicle control (febuxostat-shaped)
- DRUG Placebo, vehicle control (allopurinol-shaped)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2021-04-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02579096
The ClinicalTrials.gov registry entry for NCT02579096 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 950 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which allopurinol capsule, 100-800 mg by mouth once daily is the first listed.
NCT02579096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02579096 about?
NCT02579096 is a clinical study titled "CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat". This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attacks. These therapies have never been compared at appropriate doses. Further, they will be studied in patients with kidney disease for the first time.
What is the current status of trial NCT02579096?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 950 participants. The study started on 2017-03-06. Estimated completion is 2021-04-15.
What interventions are being tested in trial NCT02579096?
The interventions under investigation include: allopurinol capsule, 100-800 mg by mouth once daily (DRUG), febuxostat tablet 40-120 mg by mouth once daily (DRUG), Placebo, vehicle control (febuxostat-shaped) (DRUG), Placebo, vehicle control (allopurinol-shaped) (DRUG).
Who is sponsoring clinical trial NCT02579096?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.